Samantha represents issuers and investment banking firms in a wide range of capital markets transactions. Her experience spans initial public offerings, follow-on offerings, registered direct offerings, at-the-market offering programs, private investments in public equity (PIPEs), mergers and acquisitions, and transactions involving special purpose acquisition companies (SPACs).
Beyond transactional work, Samantha also guides public and private companies through corporate governance, SEC reporting and disclosure obligations, and other compliance matters. Her clients operate across the health care, life sciences, medical device, and technology sectors.
viewpoints
Recent SEC Rules and Guidance Impose New Obligations on SPACs and Reverse Mergers
May 15, 2024 | Alert | By Anne Bruno, Daniel T. Kajunski, Samantha Silver
Read about how the SEC’s final rules relating to special purpose acquisition companies (SPACs) and other shell companies, which take effect on July 1, 2024, and the agency’s recent guidance on reverse mergers are likely to impact SPAC-related transactions and alternative capital raising transactions.
News & Press
Mintz Advises on Verastem Oncology’s $250 Million Underwritten Offering
October 15, 2026|
Mintz Advises on uniQure’s $259 Million Public Offering
June 25, 2026|
Mintz Advises on Eupraxia Pharmaceuticals $63.2 Million Public Offering
February 27, 2026|
Mintz Advises on Fulcrum Therapeutics' $175 Million Public Offering
December 16, 2025|
Mintz Advises on Wave Life Sciences $402.5 Million Public Offering
December 12, 2025|
Mintz Advises on Wave Life Sciences $402.5 Million Public Offering
December 12, 2025|
Mintz Advises on Capricor Therapeutics’ $150 Million Public Offering
December 10, 2025|
Mintz Advises on Verastem Oncology’s $103 Million Public Offering
November 21, 2025|
Mintz Advises on Eledon Pharmaceuticals’ $50 Million Follow-on Offering
November 20, 2025|
Mintz Advises on uniQure's $345 Million Public Offering
September 30, 2025|
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025|
Mintz Advises on Equillium, Inc.'s up to $50 Million PIPE
August 15, 2025|
Mintz Advises on $90 Million Underwritten Offering by Rezolute
April 25, 2025|
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 1, 2024|
Publications
- Author, Federal Reserve Corporate Governance Proposal and Its Potential Effects, Review of Banking and Financial Law (2017)
Read less